Avidbiotics Corporation

Xyphos Biosciences Inc.

Pylum Biosciences, Inc.

Dana Gebhart

Dean M Scholl

David W Martin, Jr

Steven R Williams

Kyle Landgraf

Gregory Govoni

Daniel P Steiger

Tarah Baron

The present disclosure relates to the identification, cloning, and expression of a genetic locus within angenome that encodes a phage tail-like bacteriocin (PTLB), termed an enterocin. Also provided are non-natural enterocins, which have been engineered to have altered bactericidal specificity. Nucleic acid molecules encoding natural or non-natural enterocins, vector constructs containing such nucleic acids operably linked to a heterologous promoter, producer cells containing such vectors, the encoded enterocins, as well as methods of making and using such enterocins are described.

Enterocins and methods of using the same

This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands. This application further relates to modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands attached to polypeptides, in some embodiments antibodies or fragments of antibodies. This application further relates to antigen-binding peptides derived from light and heavy chain antibody variable domains, which contain two linker regions and a split variable domain.

Insertable variable fragments of antibodies and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands

This application relates generally to the production of polypeptides having specific antigen-binding properties of Fv domains, for example, insertable variable fragments of antibodies, and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands.

Insertable variable fragments of antibodies and modified &#x3b1;1-&#x3b1;2 domains of NKG2D ligands, and non-natural NKG2D ligands that bind non-natural NKG2D receptors

This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically killbacteria, dangerous pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous aerobic producer cells. Disclosed also are small, non-ORF1374 receptor binding domains (RBDs), which are incorporated into diffocins to form engineered or variant diffocins having altered killing spectra. Variant diffocins provided herein may include a heterologous RBD and its cognate base plate attachment region (BPAR), or a fused BPAR. This invention offers a potent bactericidal agent with increased thermal and pH stability, and methods for producing it, in order to kill selectivelybacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.

Diffocins and methods of use thereof

This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically killbacteria, dangerous human pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous producer cells that, unlike, do not die in the presence of oxygen. Disclosed also is the specific gene of the isolated gene cluster that determines the killing spectrum of the R-type bacteriocin and the demonstration that the killing spectra of diffocins can be altered by engineering orf1374 of the diffocin genetic locus. This invention offers a potent bactericidal agent and a means to make it in order to kill selectivelybacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.

Growing community of inventors

San Francisco, CA, United States of America

Dana Gebhart